Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Recruiting

Phase 2

Alpelisib & Endocrine TherapyAlpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Sponsor:

Marina N Sharifi

Code:

NCT04762979

Conditions

Hormone Receptor Positive Breast Carcinoma

HER2-negative Breast Cancer

PIK3CA Mutant Metastatic Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Alpelisib

Fulvestrant

Aromatase inhibitor

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-04. This information was provided to ClinicalTrials.gov by Marina N Sharifi on 2024-10-30.